Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first‐line treatment: A 15‐year follow‐up of patients with advanced follicular lymphoma in JCOG0203
Hematological Oncology · 2024
DOI: 10.1002/hon.3272 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Hematological Oncology, 2024. Verfasst von Takashi Watanabe und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Lymphoma, Follicular. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Cancer Center Research and Development Fund, Grants-In-Aid for Cancer Research from the Ministry of Health, Labour and Welfare of Japan, the Clinical Cancer Research.
Abstract (Originalsprache)
Follicular lymphoma (FL) is an indolent lymphoma that becomes aggressive due to histological transformation (HT), leading to reduced survival. Patients with FL have different clinical courses and various treatment options. Some patients exhibit shorter survival and experience disease progression within 24 months of diagnosis/treatment (POD24); the optimal treatment remains an unmet needs. Thus, identifying factors that predict shorter survival is essential to stratify treatment and prolong the survival of patients with FL. To analyze risk factors for POD24 and HT in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R‐CHOP) as first‐line treatment, we performed this post‐hoc analysis of patients with advanced indolent B‐cell lymphoma in a randomized clinical trial wherein six cycles of R‐CHOP were administered every 2–3 weeks. The primary analysis showed no differences in outcomes, which enabled the analysis of 248 patients with FL, assigned to two arms. All histopathological specimens from the 300 enrolled patients were reviewed by three expert hematopathologists. Multivariable analysis implicated Follicular Lymphoma International Prognostic Index (FLIPI) intermediate (odds ratio [OR] 2.531, 95% confidence interval [CI] 0.676–9.466) and high‐ (OR 2.236, 95% CI 0.160–31.226) risks, B symptoms (OR 2.091, 95% CI 0.747–5.851), and grade 3A (G3A) (OR 1.833, 95% CI 0.634–5.299) as risk factors for POD24. Furthermore, multivariable analysis through a median follow‐up of 15.9 years implicated G3A (OR 2.628, 95% CI 0.806–8.575) and high‐risk FLIPI (OR 4.401, 95% CI 0.186–104.377) as risk factors for HT. However, an analysis limited to the first 10 years revealed that the prognostic factors elucidated from the longer‐term analysis had a greater impact on HT. G3A and high‐risk FLIPI may independently predict POD24 and HT, thereby informing treatment stratification of patients with untreated advanced‐stage FL in future trials, particularly to address the unmet needs of patients with POD24.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
- Department of Personalized Control Science of Myeloid and Lymphoid Tumors, Mie University Graduate School of Medicine, Tsu, Japan.
- Department of Pathology, National Cancer Center Hospital, Tokyo, Japan.
- Pathology Center, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan.
- JCOG Data Center/Operation Center, National Cancer Center, Tokyo, Japan.
- Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
ORCID-Profile: Takashi Watanabe, Dai Maruyama, Kazuyuki Shimada, Michinori Ogura, Junya Kuroda, Kensei Tobinai
Förderung
- National Cancer Center Research and Development Fund
- Grants-In-Aid for Cancer Research from the Ministry of Health, Labour and Welfare of Japan
- the Clinical Cancer Research
Zitieren
APA
Watanabe, T., Matsuno, Y., Wakabayashi, M., Maruyama, D., Yamamoto, K., Kubota, N., Shimada, K., Asagoe, K., Yamaguchi, M., Ando, K., Ogura, M., Kuroda, J., Suehiro, Y., Tsukasaki, K., Tobinai, K., & Nagai, H. (2024). Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first‐line treatment: A 15‐year follow‐up of patients with advanced follicular lymphoma in JCOG0203. Hematological Oncology. https://doi.org/10.1002/hon.3272
Vancouver
Watanabe T, Matsuno Y, Wakabayashi M, Maruyama D, Yamamoto K, Kubota N, et al. Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first‐line treatment: A 15‐year follow‐up of patients with advanced follicular lymphoma in JCOG0203. Hematological Oncology. 2024. doi:10.1002/hon.3272
BibTeX
@article{Watanabe2024,
author = {Watanabe, Takashi and Matsuno, Yoshihiro and Wakabayashi, Masashi and Maruyama, Dai and Yamamoto, Kazuhito and Kubota, Nobuko and Shimada, Kazuyuki and Asagoe, Kohsuke and Yamaguchi, Motoko and Ando, Kiyoshi and Ogura, Michinori and Kuroda, Junya and Suehiro, Youko and Tsukasaki, Kunihiro and Tobinai, Kensei and Nagai, Hirokazu},
title = {Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first‐line treatment: A 15‐year follow‐up of patients with advanced follicular lymphoma in JCOG0203},
journal = {Hematological Oncology},
year = {2024},
doi = {10.1002/hon.3272}
}
EUVIMED